|
Publications:
|
Constantinidis TC, Vagka E, Dallidou P, Basta P,
Drakopoulos V, Kakolyris S, Chatzaki
E: Occupational health and safety of personnel handling
chemotherapeutic agents in Greek hospitals. Eur
J Cancer Care (Engl)
2011;20:123-131.
Xenidis N, Neanidis K, Amarantidis K, Dimopoulos P,
Chamalidou E, Pitsiava D, Tentes A, Chatzaki
E, Karakitsos P, Kakolyris S: Biweekly vinorelbine and gemcitabine
as second-line and beyond treatment in ovarian cancer. Cancer
Chemother Pharmacol 2011;67:69-73.
Amarantidis K, Xenidis N, Chelis L, Chiotis A,
Tentes A, Chatzaki E,
Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S: A dose
escalation study of docetaxel plus capecitabine in combination with
oxaliplatin in patients with advanced solid tumors. Acta
Oncol 2010;49:245-251.
Chelis L, Xenidis N, Amarantidis K, Prassopoulos P,
Chamalidou E, Neanidis K, Mikroulis D, Chatzaki
E, Karakitsos P, Kakolyris S: Biweekly vinorelbine and gemcitabine
as second-line treatment and beyond in non-small cell lung cancer. Chemotherapy
2010;56:353-358.
Kaprara A, Pazaitou-Panayiotou K, Chemonidou MC,
Constantinidis TC, Lambropoulou M, Koffa M, Kiziridou A, Kakolyris S,
Kortsaris A, Chatzaki E:
Distinct distribution of corticotropin releasing factor receptors in
human breast cancer. Neuropeptides
2010;44:355-361.
Kaprara A, Pazaitou-Panayiotou K, Kortsaris A, Chatzaki E: The corticotropin releasing factor system in cancer:
expression and pathophysiological implications. Cell
Mol Life Sci 2010;67:1293-1306.
Lambropoulou M, Papadopoulos N, Tripsianis G,
Alexiadis G, Pagonopoulou O, Kiziridou A, Liberis V, Kakolyris S, Chatzaki
E: Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2):
prognostic value and survival of endometrial cancer patients. J
Cancer Res Clin Oncol
2010;136:427-435.
Paschos KA, Charsou C, Constantinidis TC,
Anagnostoulis S, Lambropoulou M, Papachristou F, Simopoulos K, Chatzaki
E: Corticotropin-releasing hormone receptors mediate opposing
effects in cholestasis-induced liver cell apoptosis.
Endocrinology
2010;151:1704-1712.
Paschos KA, Kolios G, Chatzaki
E: The corticotropin-releasing factor system in inflammatory bowel
disease: Prospects for new therapeutic approaches.
Drug Discov Today
2009;14:713-720.
Paschos KA, Veletza S, Chatzaki
E: Neuropeptide and sigma receptors as novel therapeutic targets for
the pharmacotherapy of depression.
CNS Drugs 2009;23:755-772.
Simopoulos C, Christodoulou E, Lambropoulou M,
Tsaroucha AK, Kakolyris S, Polychronidis A, Karayiannakis AJ, Chatzaki
E: Neuropeptide urocortin 1 and its receptors are expressed in the
human liver.
Neuroendocrinology 2009;89:315-326.
Stavroulaki M, Kardassis D, Chatzaki
E, Sakellaris G, Lindschau C, Haller H, Tosca A, Krasagakis K:
Exposure of normal human melanocytes to a tumor promoting phorbol ester
reverses growth suppression by transforming growth factor beta.
J Cell
Physiol 2008;214:363-370.
Tsaroucha AK, Chatzaki
E, Lambropoulou M, Despoudi K, Laftsidis P, Charsou C, Polychronidis
A, Papadopoulos N, Simopoulos CE: Megalin and cubilin in the human
gallbladder epithelium.
Clin Exp Med 2008;8:165-170.
Dermitzaki E, Tsatsanis C, Minas V, Chatzaki
E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M,
Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN: Corticotropin-releasing
factor (CRF) and the urocortins differentially regulate catecholamine
secretion in human and rat adrenals, in a CRF receptor type-specific
manner.
Endocrinology 2007;148:1524-1538.
Lambropoulou M, Stefanou D, Alexiadis G, Tamiolakis
D, Tripsianis G, Chatzaki E,
Vandoros GP, Kiziridou A, Papadopoulou E, Papadopoulos N: Cytoplasmic
expression of c-erb-B2 in endometrial carcinomas.
Onkologie
2007;30:495-500.
Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN: The corticotropin-releasing
factor (CRF) family of peptides as local modulators of adrenal function.
Cell Mol Life Sci 2007;64:1638-1655.
Amarantidis K, Houhouli K, Papatheodorou K,
Miloussis A, Matthaios D, Chatzaki
E, Lyrantzopoulos N, Tsaroucha A, Tentes A, Kakolyris S: A dose
escalation study of docetaxel plus capecitabine in combination with
gemcitabine in patients with advanced solid tumors.
Oncol Res
2006;16:281-287.
Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, Kolios G, Kouroumalis
E, Margioris AN, Gravanis A: Neuropeptide urocortin and its receptors
are expressed in rat Kupffer cells.
Neuroendocrinology 2006;84:49-57.
Chatzaki
E, Lambropoulou M, Constantinidis TC, Papadopoulos N, Tache Y, Minopoulos
G, Grigoriadis DE: Corticotropin-releasing factor (CRF) receptor type 2
in the human stomach: protective biological role by inhibition of
apoptosis. J Cell Physiol 2006;209:905-911.
Chatzaki
E, Minas V, Zoumakis E, Makrigiannakis A: CRF receptor antagonists:
utility in research and clinical practice. Curr Med Chem
2006;13:2751-2760.
Kaklamanis L, Trichas M, Amarantidis K, Spathari N,
Micheli A, Karayiannakis A, Chatzaki
E, Georgoulias V, Kakolyris S: VEGF expression in the colorectal
adenoma-carcinoma sequence.
Oncol Res 2006;15:445-451.
Chatzaki
E, Euthymiadis C, Kyriaki S, Lambropoulou M, Tsaroucha A, Laftsidis P,
Simopoulos K: Urocortin and corticotropin-releasing hormone receptor
type 2 expression in the human gallbladder. Neuroendocrinology
2005;82:177-184.
Maltezos E, Amarantidis K, Trichas M, Vasiliadis M,
Toromanidou M, Chatzaki E,
Karayiannakis A, Tsaroucha A, Romanidis K, Kakolyris S: A dose
escalation study of pegylated liposomal Doxorubicin (caelyx) in
combination with capecitabine (xeloda) in patients with refractory solid
tumors.
Oncology 2005;69:463-469.
Chatzaki
E, Crowe PD, Wang L, Million M, Tache Y, Grigoriadis DE: CRF receptor type
1 and 2 expression and anatomical distribution in the rat colon. J
Neurochem 2004;90:309-316.
Chatzaki
E, Murphy BJ, Wang L, Million M, Ohning GV, Crowe PD, Petroski R, Tache Y,
Grigoriadis DE: Differential profile of CRF receptor distribution in the
rat stomach and duodenum assessed by newly developed CRF receptor
antibodies. J Neurochem 2004;88:1-11.
Chatzaki
E, Kouimtzoglou E, Margioris AN, Gravanis A: Transforming growth factor
beta1 exerts an autocrine regulatory effect on human endometrial stromal
cell apoptosis, involving the FasL and Bcl-2 apoptotic pathways. Mol Hum
Reprod 2003;9:91-95.
Chatzaki
E, Charalampopoulos I, Leontidis C, Mouzas IA, Tzardi M, Tsatsanis C,
Margioris AN, Gravanis A: Urocortin in human gastric mucosa:
relationship to inflammatory activity. J Clin Endocrinol Metab
2003;88:478-483.
Chatzaki
E, Margioris AN, Gravanis A: Expression and regulation of corticotropin-releasing
hormone binding protein (CRH-BP) in rat adrenals. J Neurochem
2002;80:81-90.
Gravanis A, Makrigiannakis A, Chatzaki
E, Zoumakis E, Tsatsanis C, Margioris AN: Stress neuropeptides in
the human endometrium: paracrine effects on cell differentiation and
apoptosis.
Hormones (Athens) 2002;1:139-148.
Chatzaki
E, Makrigiannakis A, Margioris AN, Kouimtzoglou E, Gravanis A: The Fas/FasL
apoptotic pathway is involved in kappa-opioid-induced apoptosis of human
endometrial stromal cells. Mol Hum Reprod 2001;7:867-874.
Krasagakis K, Almond-Roesler B, Geilen C, Fimmel S,
Krengel S, Chatzaki E,
Gravanis A, Orfanos CE: Growth and characterization of a cell line from
a human primary neuroendocrine carcinoma of the skin (Merkel cell
carcinoma) in culture and as xenograft.
J Cell Physiol 2001;187:386-391.
Zoumakis E, Chatzaki
E, Charalampopoulos I, Margioris AN, Angelakis E, Koumantakis E,
Gravanis A: Cycle and age-related changes in corticotropin-releasing
hormone levels in human endometrium and ovaries.
Gynecol Endocrinol
2001;15:98-102.
Chatzaki
E, Margioris AN, Makrigiannakis A, Castanas E, Georgoulias V, Gravanis A:
Kappa opioids and TGFbeta1 interact in human endometrial cells. Mol Hum
Reprod 2000;6:602-609.
Davies S, Bax CM, Chatzaki
E, Chard T, Iles RK: Regulation of endometrial cancer cell growth by
luteinizing hormone (LH) and follicle stimulating hormone (FSH).
Br J
Cancer 2000;83:1730-1734.
Dermitzaki E, Chatzaki
E, Gravanis A, Margioris AN: Opioids transiently prevent activation
of apoptotic mechanisms following short periods of serum withdrawal.
J
Neurochem 2000;74:960-969.
Makrigiannakis A, Margioris AN, Chatzaki
E, Zoumakis E, Chrousos GP, Gravanis A: The decidualizing effect of
progesterone may involve direct transcriptional activation of
corticotrophin-releasing hormone from human endometrial stromal cells.
Mol Hum Reprod 1999;5:789-796.
Bax CM, Chatzaki
E, Davies S, Gallagher CJ: Elucidating the role of gonadotrophins in
endometrial cancer cell growth.
Biochem Soc Trans 1996;24:443S.
Chatzaki
E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ: The
expression of gonadotropin-releasing hormone and its receptor in
endometrial cancer, and its relevance as an autocrine growth factor.
Cancer Res 1996;56:2059-2065.
Chatzaki
E, Gallagher CJ, Iles RK, Ind TE, Nouri AM, Bax CM,
Grudzinskas JG: Characterisation of the differential expression of
marker antigens by normal and malignant endometrial epithelium. Br J
Cancer 1994;69:1010-1014.
|
